Request Demo
Last update 17 Oct 2026
Lithium gamolenate
Last update 17 Oct 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Glamolec, LiGLA, Lithium-gamma linolenate + [3] |
Target |
Action stimulants |
Mechanism Prostaglandin synthases stimulants |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H30LiO2 |
InChIKeyPULYXVPPEOPWIV-HPFCUAHCSA-N |
CAS Registry122051-95-0 |
Related
1
Clinical Trials associated with Lithium gamolenateNCT00612807
Adapting Marital Therapy in Older Adults With Depression
100 Clinical Results associated with Lithium gamolenate
Login to view more data
100 Translational Medicine associated with Lithium gamolenate
Login to view more data
100 Patents (Medical) associated with Lithium gamolenate
Login to view more data
9,068
Literatures (Medical) associated with Lithium gamolenate01 Dec 2026POULTRY SCIENCE
Ahiflower seed and press cake with or without multi-enzyme supplementation in broiler chicken diets: implications on growth performance, nutrient digestibility, gut morphology, bone characteristics, gizzard weight, and meat fatty acid profiles
Article
Author: Ogory, Roseline O ; Lawrence-Azua, Ann Sewuese ; Adewole, Deborah
The effects of multi-enzyme supplementation (ES) in diets with 10% ahiflower seed (AS) or presscake (APC) on growth, nutrient digestibility, intestinal morphology, gizzard weight, bone characteristics, and meat fatty acids (FAs) in broiler chickens were evaluated. One-day-old Ross 308 broiler chicks were housed 15/pen and assigned to six diets in a 3 × 2 factorial arrangement, including a corn-soybean control (CON), CON+10%AS, and CON+10%APC, with or without ES, for 35d, in a randomized complete block design with six pens/treatment. Overall, body weight (BW) and BW gain (BWG) were reduced by 10%AS and 10%APC (P = 0.0001), while only 10%AS reduced feed intake. Without ES, 10%APC increased FCR, but with ES, no negative effect of APC was observed. Compared to CON, 10%AS increased the duodenal villus height (VH; P = 0.0064), jejunal VH (P = 0.0488), and jejunal villus height: crypt depth (VH:CD; P = 0.0284), while 10%APC increased VH:CD in the ileum (P = 0.0332). Phosphorus digestibility was reduced by 10%AS (P = 0.0381) and ES (P = 0.0396), whereas calcium digestibility was unaffected by diet, ES, or interaction. Crude protein digestibility showed a diet × ES interaction (P = 0.0211), where lower value was observed for 10%AS than CON, only when enzyme was supplemented. Gizzard weight was increased in birds fed 10%APC compared with CON (P = 0.0020), with no ES effect. The bone breaking strength of the right tibia was higher in 10%AS than in 10%APC (P = 0.0211). Compared to CON, tibia weights were lower in 10%APC (P = 0.0207 and 0.0491, for right and left tibia, respectively), with no ES effect. In the breast meat, 10%AS increased stearidonic acid (SDA; P = 0.0467) and improved omega-6:omega-3 (P < 0.0001). In the thigh meat, 10%AS increased (P < 0.001) the contents of SDA, gamma linolenic acid, and total polyunsaturated FAs, compared to CON. Both 10%AS and 10%APC increased (P < 0.0001) the contents of alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and total omega 3 FAs in the thigh meat, while improving the omega-6:omega-3, compared to CON (P < 0.0001). There was a significant interaction (P = 0.0002) between ES and diet in Omega-6:Omega-3, with a better ratio in CON+ES than CON-ES. In conclusion, though 10%AS and 10%APC reduced BW and BWG, they increased the concentrations of polyunsaturated FAs in the thigh meat, with 10% AS also increasing SDA concentration in the breast meat and increasing right tibia breaking strength. While 10%AS improved intestinal morphology in the duodenum and jejunum, 10%APC improved it only in the ileum.
01 Nov 2026PHYTOMEDICINE
Chemical characterization and pharmacological mechanisms of Qizhi Yishen Capsule in early diabetic kidney disease
Article
Author: Duan, Wenna ; Shang, Guichun ; Zhang, Yongqing ; Liu, Yan ; Jiang, Qiu ; Liu, Jingbo
OBJECTIVE:
This research explored the bioactive components and therapeutic mechanisms of Qizhi Yishen Capsule (QZC) in managing early-stage diabetic kidney disease (DKD) by integrating network pharmacology with experimental evidence, aiming to support its clinical utility with scientific validation.
METHODS:
Network pharmacology and molecular docking were utilized to identify QZC's potential targets in DKD treatment. The therapeutic impact of QZC on renal damage in DKD rats was assessed through in vivo tests, including serum biochemistry, histological staining, and transmission electron microscopy analysis.Potential mechanisms were further explored through metabolomics, in vitro experiments, qRT-PCR, and Western blot analysis.
RESULTS:
The renal protective effects of QZC in DKD were predicted to be mediated via signaling pathways such as PI3K-Akt, AMPK, and MAPK, based on network pharmacology analysis. In vivo studies confirmed that QZC (509 mg·kg-1), in combination with metformin hydrochloride tablets (MET, 104 mg kg-1), significantly alleviated pathological renal injury and improved podocyte ultrastructure in DKD rats. Metabolomics analysis identified 420 candidate biomarkers, of which 157 were upregulated in the DKD model group and downregulated after QZC treatment, and 263 showed the opposite trend. These metabolites were mainly involved in starch and sucrose metabolism, tyrosine metabolism, phenylalanine metabolism, cysteine and methionine metabolism, and the biosynthesis of phenylalanine, tyrosine, and tryptophan. In vitro assays demonstrated that QZC (300 μg ml-1), gamma-linolenic acid (GLA, 12 μmol L-1), and methyl caffeate (MC, 12 μmol L-1)-two active constituents of QZC-significantly inhibited apoptosis in HK-2 cells, regulated the cell cycle, and reduced reactive oxygen species (ROS) levels. qRT-PCR and Western blot analyses indicated that QZC activated AMPK, SIRT1, and PGC-1α expression at the mRNA and protein levels.
CONCLUSION:
QZC improves hyperglycemia-induced tubular injury and metabolic disorders in DKD rats by suppressing oxidative stress and apoptosis through multi-component and multi-target regulation of the AMPK/SIRT1/PGC-1α signaling pathway. This study integrates network pharmacology, metabolomics, and experimental validation to systematically elucidate, for the first time, the multi-component basis and the AMPK/SIRT1/PGC-1α pathway mechanism underlying QZC's efficacy against early DKD.
01 Oct 2026FOOD RESEARCH INTERNATIONAL
Dietary resveratrol improves meat quality in lambs via the rumen-muscle axis mediated by reshaped microbial metabolism
Article
Author: Hu, Fengming ; Lv, Xiaokang ; Ma, Tao ; Sun, Tongyu ; Zhuang, Yimin ; Bi, Yanliang
Resveratrol (RSV) is a plant-derived polyphenol known to enhance host health and growth in animals. In this study, we used integrated metagenomic and metabolomic approaches to show that dietary RSV reshapes the rumen microbiome and its metabolism. Specifically, RSV upregulated volatile fatty acid (VFA) and amino acid synthesis pathways while suppressing methanogenesis in finishing lambs. These microbial metabolic changes propagated along a rumen-muscle axis, driving compositional improvements, as evidenced by elevated polyunsaturated fatty acids (gamma-linolenic acid) and key amino acids (Ser, Ala, Ile, and Leu), as well as enhanced meat quality traits, including reduced drip loss, increased eye muscle area, and improved color stability. Microbiota-muscle correlation analyses further linked the signature rumen microbes with muscle nutritional indicators. Our findings delineate a clear microbe-metabolite-tissue pathway through which RSV influences mutton quality, offering a mechanistic basis for microbiome-guided strategies to optimize meat production in ruminants.
1
News (Medical) associated with Lithium gamolenate
100 Deals associated with Lithium gamolenate
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 3 | United Kingdom | 01 May 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free